Proteogenomics of clear cell renal cell carcinoma response to tyrosine kinase inhibitor.

Examination of patients’ clinical parameters showed that responders and non-responders presented highly significant differences in both progression-free survival (Fig. 1c , log-rank p < 0.0001) and overall survival (Fig. 1c , log-rank p < 0.0001).

also in 132,142 other papers